IP Library Granted Patent US 11,878,002
Granted Patent B2
US 11,878,002 · App. 17/225,513 · Granted Jan 23, 2024

Methods and materials for using

Inventors: Purna C. Kashyap (Rochester, MN); Michael Fischbach (Portola Valley, CA); Brianna B. Williams (Oakland, CA)
Assignees: Mayo Foundation for Medical Education and Research; Regents of the University of California
A61K31/405A61K35/74A61K35/741A61K35/742A61K2035/115Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,878,002
App. No.
17/225,513
Granted
Jan 23, 2024
Kind
B2
Abstract

This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

Claims (10)

1. A method for treating a gastrointestinal disorder in a human, wherein said method comprises:

(a) identifying said human as having said gastrointestinal disorder, and

(b) administering a composition comprising at least one live Clostridium sporogenes to said human under conditions wherein gastrointestinal function of said human is improved.

2. The method of claim 1 , wherein said gastrointestinal disorder is irritable bowel syndrome.

3. The method of claim 1 , wherein said composition comprises at least one bacterial organism comprising exogenous tryptophan decarboxylase activity.

4. The method of claim 3 , wherein said at least one bacterial organism comprising exogenous tryptophan decarboxylase activity is Escherichia coli or Bacteroides thetaiotaomicron.

5. The method of claim 1 , wherein said composition is a pill, tablet, or capsule.

6. The method of claim 5 , wherein said pill, tablet, or capsule is configured to deliver said live Clostridium sporogenes to the intestines of said human.

7. The method of claim 3 , wherein said at least one bacterial organism comprises exogenous nucleic acid encoding a polypeptide having tryptophan decarboxylase activity.

8. The method of claim 7 , wherein said exogenous nucleic acid encodes a tryptophan decarboxylase derived from Ruminococcus gnavus.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2024
From: KASHYAP, PURNA C.; FISCHBACH, MICHAEL
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 069249/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2024
From: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
To: FISCHBACH, MICHAEL
Reel/Frame 069249/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2024
From: FISCHBACH, MICHAEL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 069249/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2024
From: WILLIAMS, BRIANNA B.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 069249/0768 →
CONFIRMATORY LICENSE Recorded Nov 10, 2023
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065547/0951 →
Continuity (4)
Continuation 16388405 · Apr 18, 2019
Continuation 15235782 · Aug 12, 2016
Provisional Application 62204270 · Aug 12, 2015
Related Publication 20220062235A1 · Mar 3, 2022
Cited By (1)
US 12,257,235